Celgene Corp (CELG)

CELG (NASDAQ:Drugs)
$106.94
pos +1.80
+1.71%
Today's Range: 104.18 - 107.35 | CELG Avg Daily Volume: 4,765,500
Last Update: 10/30/14 - 4:00 PM EDT
Volume: 5,748,804
YTD Performance: 24.45%
Open: $104.70
Previous Close: $105.14
52 Week Range: $66.85 - $106.28
Oustanding Shares: 799,510,100
Market Cap: 84,508,217,570
6-Month Chart
TheStreet Ratings Grade for CELG
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 16 16 16 16
Moderate Buy 1 1 1 0
Hold 2 3 4 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.26 1.35 1.43 1.40
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 55.34
Price Earnings Comparisons:
CELG Sector Avg. S&P 500
55.34 55.30 27.09
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
19.84% 35.39% 217.69%
GROWTH 12 Mo 3 Yr CAGR
Revenue 17.90 0.79 0.21
Net Income -0.40 0.65 0.18
EPS 2.00 0.84 0.22
Earnings for CELG:
EBITDA 2.35B
Revenue 6.49B
Average Earnings Estimates
Qtr (12/14) Qtr (03/15) FY (12/14) FY (12/15)
Average Estimate $0.88 $n.a. $3.26 $4.40
Number of Analysts 4 0 2 4
High Estimate $0.91 $n.a. $3.26 $4.94
Low Estimate $0.85 $n.a. $3.26 $4.09
Prior Year $0.67 $0.73 $2.68 $3.26
Growth Rate (Year over Year) 32.33% n.a.% 21.64% 34.97%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Oct 30, 2014 | 2:31 PM EDT

Still, it's a good time to review what's happening, so we never forget.

By

Jim Cramer

 | Oct 29, 2014 | 12:42 PM EDT

The Fed event can actually be good for many stocks.

By

Ed Ponsi

 | Oct 28, 2014 | 10:00 AM EDT

The next step is to know how much risk you can bear.

By

Bret Jensen

 | Oct 24, 2014 | 2:00 PM EDT

I invest in biotech in a different way than any other sector.

By

Doug Kass

 | Oct 24, 2014 | 8:50 AM EDT
From The Street of Dreams

bullishCelgene price target raised at Deutsche

Oct 24, 2014 | 7:42 AM EDT

CELG price target raised to $134 from $115, said Deutsche. Company has emerged as having best pipeline in biotech group. Rating remains Buy.

By

Jim Cramer

 | Oct 23, 2014 | 4:42 PM EDT

I could have selected several others as well.

By

Doug Kass

 | Oct 23, 2014 | 7:36 AM EDT
Where it began.
By

Jim Cramer

 | Oct 21, 2014 | 1:28 PM EDT

Welcome back to the airlines and the biotechs.

By

Timothy Collins

 | Sep 25, 2014 | 9:58 AM EDT

Technical indicators have now swung in the bears' favor.

Good day in market with DJIA leading the gains, albeit with a big assist from Visa (V) whi...
Textron is beginning to look somewhat extended. With today's slight advance the stoc...
The Fibocall: Twitter updated from October 28 "All is not lost, though, as the stock is ab...
The Fibocall: Amazon updated from October 24 (DAY 1) "Readers of The Fibocall know that we...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.